{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T22:25:57Z","timestamp":1794954357026,"version":"4.9.1"},"reference-count":41,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T00:00:00Z","timestamp":1285804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2011,2]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Purpose:\u2002<\/jats:bold>\n                    Brivaracetam (BRV) is a new anticonvulsant under development. Although BRV is an analog of levetiracetam (LEV), in addition to being an SV2A ligand, it also inhibits sodium channels in a voltage\u2010dependent manner. The cognitive effects of BRV are uncertain.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    A randomized, double\u2010blind, placebo\u2010controlled, four\u2010way cross\u2010over design was employed in 16 healthy volunteers comparing acute dosing (i.e., two doses) of BRV 10\u2003mg, LEV 500\u2003mg, lorazepam (LZP) 2\u2003mg, and placebo. The primary outcome was the summary score from the cognitive neurophysiologic test (CNT), which combines electrophysiologic and performance measures. Secondary outcomes included CNT cognitive and electrophysiologic subscores, traditional neuropsychological measures, and treatment\u2010emergent adverse events (TEAEs).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Compared to BRV, LEV, and placebo, LZP adver\u2010sely affected the CNT summary score and the majority of CNT subscores and neuropsychological measures. In contrast, BRV did not differ from placebo or LEV on any measure. More TEAEs occurred with LZP compared to each of the other treatment conditions.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Discussion:\u2002<\/jats:bold>\n                    The differential pattern of drug effects was consistent across multiple electrophysiologic, cognitive, and subjective measures. The profile of cognitive, subjective, and electrophysiologic effects for BRV was similar to the analog compound LEV and to placebo. The findings suggest that BRV should be tolerated well from a neuropsychological perspective, but additional studies are needed.\n                  <\/jats:p>","DOI":"10.1111\/j.1528-1167.2010.02746.x","type":"journal-article","created":{"date-parts":[[2010,9,30]],"date-time":"2010-09-30T17:34:45Z","timestamp":1285868085000},"page":"264-272","source":"Crossref","is-referenced-by-count":47,"title":["Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam"],"prefix":"10.1111","volume":"52","author":[{"given":"Kimford J.","family":"Meador","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Gevins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip T.","family":"Leese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Otoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Loring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,9,30]]},"reference":[{"issue":"11","key":"e_1_2_7_2_1","first-page":"106","article-title":"Brivaracetam as adjunctive treatment of refractory partial\u2010onset seizures in adults: results from two randomized, double\u2010blind, placebo\u2010controlled trials","volume":"50","author":"Biton V","year":"2009","journal-title":"Epilepsia"},{"key":"e_1_2_7_3_1","volume-title":"Test of non\u2010verbal intelligence","author":"Brown L","year":"1996"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-2457(02)00067-6"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00427897"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181ec7f7f"},{"key":"e_1_2_7_7_1","first-page":"1018","article-title":"Detecting transient cognitive impairment with EEG pattern recognition methods","volume":"70","author":"Gevins A","year":"1999","journal-title":"Aviat Space Environ Med"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(79)90297-9"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(79)90296-7"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1518\/001872098779480578"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(01)00300-1"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-003-0014-0"},{"key":"e_1_2_7_13_1","volume-title":"The Stroop color and word test: a manual for clinical and experimental uses","author":"Golden CJ","year":"2002"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1868-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-200509000-00023"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.49704.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000271385.85302.55"},{"issue":"6","key":"e_1_2_7_18_1","first-page":"328","article-title":"Dose\u2010 and exposure\u2010response modeling of brivaracetam add\u2010on treatment in patients with partial epilepsy","volume":"48","author":"Laveille C","year":"2007","journal-title":"Epilepsia"},{"key":"e_1_2_7_19_1","volume-title":"Antiepileptic drugs","author":"Levy RH","year":"2002"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01323.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.198"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-2457(99)00258-8"},{"key":"e_1_2_7_23_1","volume-title":"POMS manual: profile of mood states","author":"McNair DM","year":"1992"},{"key":"e_1_2_7_24_1","volume-title":"The treatment of epilepsy: principles & practice","author":"Meador KJ","year":"2010"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02389.x"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000281104.55418.60"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.03.006"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjp.2008.221"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03158.x"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(91)90203-G"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02829.x"},{"key":"e_1_2_7_33_1","volume-title":"Symbol digit modalities test. Manual","author":"Smith A","year":"1973"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1162\/jocn.1993.5.1.1"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/0013-4694(93)90046-X"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00508.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.11.006"},{"key":"e_1_2_7_38_1","volume-title":"A compendium of neuropsychological tests: administration, norms and commentary","author":"Spreen O","year":"1998"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1586\/ecp.09.16"},{"key":"e_1_2_7_40_1","unstructured":"UCB Investigator\u2019s Brochure for Brivaracetam (UCB 34714). Reference RXCE08A1101 Version 8 Final of 21 Feb2008a."},{"key":"e_1_2_7_41_1","unstructured":"UCB Investigator\u2019s Brochure for Levetiracetam (UCB LO59 Keppra\u00ae). Reference RXCE07M1913 Final of 25 Jan2008b."},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.09.024"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2010.02746.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2010.02746.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T12:42:30Z","timestamp":1697373750000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2010.02746.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,30]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["10.1111\/j.1528-1167.2010.02746.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2010.02746.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,30]]}}}